The three Finalists were: *Click Therapeutics — pitch by David Klein, Co-Founder & CEO *AUGMENTx (WINNER) — pitch by Dr. Albert Kwon, Co-Founder & CEO *Sincrolab — pitch by Ignacio de Ramon, Co-Founder & CEO *Judged by: Alexandra Morehouse, Chief Marketing Officer at Banner Health; Colin Milner, Founder and CEO of the International Council on Active Aging (ICAA); Danny Dankner, CEO and Co-founder of Applied Cognitive Engineering; Zack Lynch, General Partner at JAZZ Venture Partners *Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains *Sarah Lenz Lock, Senior Vice President for Policy at AARP and Executive Director of the Global Council on Brain Health (GCBH) *Dr. April Benasich, Director of the Baby Lab at the Rutgers Center for Molecular and Behavioral Neuroscience *Chaired by: Dr. Cori Lathan, Co-Chair of the World Economic Forum’s Council on the Future of Human Enhancement Slidedeck supporting session held during the 2017 SharpBrains Virtual Summit: Brain Health & Enhancement in the Digital Age (December 5-7th). Learn more at: https://sharpbrains.com/summit-2017/

1. 2017 SHARPBRAINS VIRTUAL SUMMIT

3. Top Brainnovations to Improve Brain Health & Performance
Click Therapeutics — pitch
by David Klein, Co-Founder &
CEO
AUGMENTx — pitch
by Dr. Albert Kwon, Co-Founder
& CEO
Sincrolab — pitch by Ignacio
de Ramon, Co-Founder &
CEO

4. Judges
Alexandra Morehouse, Chief
Marketing Officer at Banner
Health
Colin Milner, Founder and
CEO of the International
Council on Active Aging
(ICAA)
Danny Dankner, CEO and
Co-founder of Applied
Cognitive Engineering
Zack Lynch, General Partner
at JAZZ Venture Partners

5. 2017 SHARPBRAINS VIRTUAL SUMMIT

6. MISSION: TO BECOME
THE LEADING DIGITAL THERAPEUTICS PROVIDER AND PLATFORM
• We create, validate and commercialize software as treatments
• These Digital Therapeutics™ are based on our clinically validated platform
• They work independently or in conjunction with pharmacotherapies
• Data collected are used to continuously improve & personalize interventions
• Unique and robust intellectual property strategy and portfolio
• Better outcomes through user engagement and neurobehavioral change
2
2017 SHARPBRAINS VIRTUAL SUMMIT

7. PIPELINE
CT-100: CLICK Neurobehavioral Intervention (CNI) Platform
Chronic Pain
CT-130
Insomnia
CT-141
Clickadian™
PRODUCT INDICATION RESEARCH DEVELOPMENT PILOT STUDY EFFICACY TRIAL
Myocardial Infarction
CT-111
Clickheart™
CT-152
Major Depressive DisorderClickEFMT™
Depressed Mood
CT-151
Clickarise™
Smoking Cessation
CT-101
Clickotine©
2017 SHARPBRAINS VIRTUAL SUMMIT

8. NOVELTY
ClickEFMT™: A DIGITAL TREATMENT FOR DEPRESSION
4
EFMT targets the imbalance between hyperactive (RED) emotion processing regions and hypoactive
(BLUE) prefrontal regions underlying the cognitive control impairments observed in MDD patients
Emotion Recognition
and Processing
Working
Memory
Emotional Faces Memory Task (EFMT) helps patients with Major Depressive
Disorder (MDD) enhance cognitive control over emotion by practicing
emotion recognition and working memory together
2017 SHARPBRAINS VIRTUAL SUMMIT

9. RESEARCH
COMPLETED 2 RCTS, AND 1 fMRI STUDY
5
Intervention
Effective and functional connectivity
between key neural nodes investigated
pre-post EFMT training
c) Expectation of benefit and ability to blind: participants in
TAU and no contact controls would know immediately which
trial arm they were in. With SMT, patients were made aware
they were participating in a “study of 2 cognitive training
exercises, and will be assigned to one or the other to
complete over 6 weeks.” Thus, both conditions could
plausibly deliver benefit, clinical equipoise would apply, and
patients and investigators could remain blinded to
hypothesis.
Considered three control conditions for the studies: no-contact, treatment as usual (TAU), and Shapes Memory Task
(SMT), an interactive task matched to EFMT with non-emotional stimuli, and concluded that SMT is the best control for
EFMT for the following reasons:
a) Time and effort: participants
completed the same number of
sessions in both conditions at the
time selected by the participant. In
TAU, time spent in therapy or using
medication would be too variable to
offer an accurate control.
b) Clinician/staff attention:
participants in both trial arms will
received the same engagement with
a clinician or staff member whereas
patients in a no-contact or TAU
control would receive variable
attention from clinician and staff
members.
Sham Control
2017 SHARPBRAINS VIRTUAL SUMMIT
fMRI Study
vs.

10. Preparing a multi-center, randomized, controlled,
parallel group, FDA phase III registration study
RESEARCH CONTINUED
POSITIVE RESULTS FROM THESE TRIALS AND NEXT STEPS
6
Pilot study Completed Clinical Trial Completed fMRI study
11 EFMT vs. 10 Control
1
28 EFMT vs. 23 Control
2 3
NEXT RESEARCH STEP:
EFMT demonstrated a significant reduction of HAM-D
scores from baseline to outcome (from 21.55 to
10.91) that was greater than CT (from 19.80 to
14.10); F(1,19)= 5.605, p= .029. Error bars indicate ±
1 standard error. * p < .05 between groups.
Published: Iacoviello et al. (2014),
Depression & Anxiety
Data replicated EFMT efficacy
observed in pilot study.
Objective fMRI data support
our hypothesis that EFMT has
a neuroplastic effect.
Publication: Under review Publication: In preparation
*Discuss more in presentation
*Discuss more in presentation *Discuss more in presentation
2017 SHARPBRAINS VIRTUAL SUMMIT
Effective and functional connectivity between
key neural nodes investigated
pre-post EFMT training

11. SCALABILITY
LAYING GROUNDWORK FOR WIDESPREAD COVERAGE AND SCALE
Electronic Medical Records
Digital nature allows for direct
integration with
Upon FDA clearance, ClickEFMT will
be prescribed by physicians
Commercial
Behavioral
Commercial
Specialty
Government
Pharmacy
Management
25.7 25.2
5.1 15
Our largest
investor Magellan
Health helping to
garner
widespread
reimbursement
and to lay the
groundwork to
scale ClickEFMT
Performance and
efficacy can
improve as
more patients are
treated with
ClickEFMT and
data are used to
optimize treatment
EFFICACY
2017 SHARPBRAINS VIRTUAL SUMMIT
COVERED LIVES (Millions)
7

12. SCALABILITY CONTINUED
ORGANIZING FOR IMMEDIATELY ENABLED PATIENT ACCESS
Physician prescribes
exactly the same as they
would a drug
Physician sees specific
therapeutic choices and
coverage for each patient
Click + Magellan
structuring system
integrations across the
nation
2017 SHARPBRAINS VIRTUAL SUMMIT
8

13. PATENT FILINGS INCLUDE:
• Systems and Methods for Treating a Psychiatric Disorder. U.S. Patent Application No. 15/513490
• Claims directed to:
Systems and computer products for conducting a therapy session by sequentially displaying subsets of images
capable of inducing human amygdala activation and modifying a number of images between two images
showing the same emotion based on responses to queries
• Pending applications in AU, CA, EP and JP
• Systems and Methods for Improving Efficiency of a Remote Computing Device. U.S. Patent Application
No. 15/348777
• Claims directed to:
Systems and methods for determining a time at which to send a subsequent message (just in time intervention)
to a patient’s monitoring device based on a patient’s response to a previous message
• Therapeutic System and Remote Patient Monitoring Device. U.S. Patent Application No. 15/563477
• Claims directed to:
A medical treatment system and method configured to i) generate a treatment plan corresponding to the patient,
the treatment plan including a plurality of events (missions/notifications) generated based on the patient profile
and ii) modify the treatment plan in response to previous feedback to the events received from the patient,
INTELLECTUAL PROPERTY
UNIQUE & ROBUST IP STRATEGY & PORTFOLIO
9
*Discuss more in presentation
2017 SHARPBRAINS VIRTUAL SUMMIT

14. IMPACT
SO WHAT?
10
16.5M adults
with MDD1
Major Depression in the U.S.
75%
would prefer non-
pharmacologic
treatment2
2. McHugh et al., Journal of Clinical Psychiatry
~50% of those
diagnosed with MDD
receive treatment1
Non-pharmacologic
treatment options are
limited
Cognitive behavioral
therapy is not widely
available
~60% of those
diagnosed with MDD
also experience
significant anxiety
symptoms3
1. NIMH 3. Coplan et al., World Journal of Psychiatry
2017 SHARPBRAINS VIRTUAL SUMMIT

15. Current U.S. healthcare spending on chronic
care is unsustainable.
Launch of ClickEFMT
FDA registration study
2018
Magellan makes
substantial financial
investment into Click
2017
Addressable
market
>$9
billion
Potential peak sales
for ClickEFMT alone
>$1
billion
United States
Economic
burden of
depression3
$210
billion
% of total
spending towards
chronic care2
86%
Total U.S.
healthcare
spending1
$3.2
trillion
FINANCIAL SUSTAINABILITY
THE NUMBERS
Click completes
landmark digital
therapeutic clinical trial
Magellan completes
successful Clickotine
commercial pilot
2016
2016
2. CDC1. CMS 3. APA
2017 SHARPBRAINS VIRTUAL SUMMIT
11

16. accelerates neurological recovery with AR

19. Need access to trained therapist at first
Poor compliance
No performance metrics nor reporting
Bulky
On-demand & digital assisted therapy
Better compliance through engagement
Automated progress reports
Small form factor
Mirror Box Therapy

20. Inpatient Hospitals
~1 year
B2B
Outpatient Clinics
~1 year
B2B
Home Therapy
~2-3 years
B2C
Cloud Data
Analytics
B2B
Public Health
& Interventions
B2G
Go-to-Market and Reimbursement Strategies
Each therapy session can be reimbursed through current billing codes
*
* *

21. Y2Start
Clinical Trial
FDA 510(k)
Pilot Clinical
Programs
2018
Y1Preclinical
Product
Development
&
Plan Clinical
Trials
2017
Y3Focus on
Sales &
Marketing
2019

22. ALBERT KWON
MIT, Harvard MD
Pediatrician, Anesthesiologist
Bioengineer, Biologist
JULIEN BOUVIER
ENSIMAG
IT Engineer, AR Expert
Amadeus
SERGIO NAVARRO
MIT, Baylor MD
Future Surgeon
VP of Finance at Goldman Sachs
Mechanical Engineer
MEHDI LEFOUILI
U.T. de Compiegne
IT Engineer, R&D
Amadeus
JINGRU GUO
Parsons, RISD
UI/UX Expert
Amazon Alexa

23. @augmentx_rehab @augmentx@augmentxrehab
Albert Kwon, M.D.
albert.kwon@augmentx.rehab

24. CO-FOUNDER CEO
Ignacio de Ramón

25. Neuropsychologists offers:
personalized treatments, but little
recurrence and high price.
The drugs offer: recurrence and cost
reduction but it is not very specific
yet (general mechanisms of action
that do not take into account the
variability of the subject).
Gamification Apps
Laboratory
Paradigms
Sincrolab uses AI and dual tasks (which allow cognitive stimulation according to the new
paradigm of cognitive stimulation). In addition, it allows to make measurements of the training
with the precision of clinical trials.
25

26. 1909 1949 1990 2015
If the concept of the brain has changed,
shouldn’t the cognitive stimulation concept ?
2010
26

27. Functional
connectivity
Dual taskSmall-world
27

28. Same game
but different
characteristics
Receive data from previous
training and analyze them.
Cognitive Profile 1
Cognitive Profile 2
Generate a
new training
Generate a
new training
28

29. Cognitive Profile
Create personalized
trainings automatically
based on your patients’
cognitive profile
Dashboard for Patients
With Sincrolab you will
have constant and detailed
information on the
performance and each and
every one of your patients.
Dashboard for Therapist
With Sincrolab you have
everything you need to
organize your patients
data, whether you work on
your own or you have a
center with several
employees.
Tasks for children
We help health professionals
manage and generate
personalized cognitive
training plans for children
with neurodevelopmental
disorders.
Tasks for adults
Focused on stimulate
impaired cognitive processes
in neurodegenerative
disorders.
29

30. 75% of the cognition tests
have a tendency in favor
of the SINCROLAB group
42% of the behavioral
tests have a tendency in
favor of the SINCROLAB
group
SIGNIFICANT INCREASE OF FUNCTIONAL CONNECTIVITY
BETWEEN PRE AND POST TRAINING PHASE IN THE
EXPERIMENTAL GROUP
Neuropsychological and Behavioral Assessment
Our Researches
30
Adhd

31. 788
0
200
400
600
800
1000
1Q 2Q 3Q
Active Patients
13346
0
5000
10000
15000
1Q 2Q 3Q
Games Played
31
5
LICENSES
10
LICENSES
50
LICENSES
BASIC PRO ENTERPRISE
49€ 89€ 99€
20%
18%
26%
30%
84%
0% 20% 40% 60% 80% 100%
6 mths
5 mths
4 mths
3 mths
2 mths
% Engagement

32. 2014 / 2016
4 partnerships
1 clinical trial
3 Apps
1 Ai
1 App/Web
R&D 45 Customers
1000 patients
80% engage > 3 months
35.000$ Rev
2 countries
Seed Round 100.000$
200 Customers
5000 patients
80% engage >6 months
>500.000$ Rev
5 countries
Series A 1.000.000$
Customers
Trialing
México
Colombia
Paraguay
Chile
Spain
2017e 2018e
1 clinical trial 1 clinical trial
32

33. join us!
www.sincrolab.es
Nacho De Ramón
nacho@sincrolab.es
M: +34 630 36 44 25
10

35. Thank you, Speakers & Participants!

36. Thank you, Summit Sponsors!

37. Thank you, Summit Partners!

38. To learn more, visit sharpbrains.com